1. A pharmaceutical composition for the sustained release of trimetazidine, where: - the inner phase contains trimetazidine； - the outer layer contains a retardant and an anti-agglomerating agent. A composition according to claim 1, characterized in that the retardant is selected from ethyl cellulose, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, cellulose acetate phthalate, hydroxypropyl methylcellulose acetate and / or polymethacrylate acetate. 3. A composition according to claim 1, characterized in that the anti-agglomerating agent is selected from talc, colloidal silicon dioxide, magnesium stearate, stearic acid and / or fumaryl sodium stearate. 4. A composition according to claim 1, characterized in that the outer layer comprises a plasticizer. 5. The composition according to p. 4, characterized in that the plasticizer is selected from acetyl tributyl citrate, glycerol triacetate, acetyl triethyl citrate, acetyl ethyl citrate, diethyl sebacate, dibutyl sebacate, ethyl and dibutyl phthalate, glycol polyethylene and / or glycerol / or .6. A composition according to claim 1, characterized in that the percentage of retardant is strictly less than 9% of the total weight of the internal phase. A composition according to claim 1, characterized in that the percentage of retardant is in the range from 5.5% to 8% inclusive of the total weight of the internal phase. A composition according to claim 1, characterized in that the percentage of anti-agglomerating agent is in the range from 25% to 200% inclusive of the weight of the retardant. The composition in accordance with p. 4, characterized in that the percentage of plasticizer is in the range from 5%1. Фармацевтическая композиция для пролонгированного высвобождения триметазидина, где:- внутренняя фаза содержит триметазидин；- наружный слой содержит ретардант и анти-агломерирующее средство.2. Композиция в соответствии с п. 1, отличающаяся тем, что ретардант выбирают из этилцеллюлозы, ацетат
